



Acute Leukemia Working Party **NEWSletter, March 2015**

Dear Friends and Colleagues,

It is a great pleasure to send you the latest newsletter of the Acute Leukemia Working Party (ALWP) of the EBMT, presenting our current structure and activities, including education, promotion and support to prospective and retrospective clinical trials. We also take the opportunity to invite all EBMT members to design and submit new study proposals as well as to participate in our meetings.

The number of HSCT procedures for acute leukemia is continuously increasing, as reflected by growing content of our registry. On one hand, it gives large opportunity to widely investigate various areas of research, on the other, it requires appropriate organization in order to ensure the effectiveness of our work. Currently, over 70 studies are being conducted or discussed. To coordinate such activity, in 2014 we increased the number of subcommittees dedicated to coordinate the studies selection and their conduct. Please, find below their list with respective leaders and their contact addresses.

New study proposals may be submitted in a form of synopsis to the ALWP chairman and appropriate subcommittee leaders. Unfortunately, we cannot guarantee acceptance of all projects. Before approval they must be evaluated for both scientific value and feasibility. These issues may be discussed during our business meetings held twice a year. The

upcoming one is planned during the EBMT Meeting in Istanbul, on Monday, 23rd March 2015, between 7:00-9:00 (Room 3B/07). All EBMT members are cordially welcome.

The productivity of the ALWP is huge as reflected by the number of scientific publications and meeting abstracts. Below, please find the list of papers published or accepted in 2014 as well as oral presentations during the ASH 2014 meeting. I would also like to draw your attention to the ALWP papers, which will be presented during the EBMT 2015 meeting and invite you to participate in the ALWP plenary session (33rd March 2015, 13:45–15:15, Harbiye Auditorium).

Apart from the scientific activity, the ALWP is proud of the educational events organized annually in various European countries. The symposia held in Milan 2010 and Warsaw 2011 gave an opportunity for transplanters to meet leaders of the AML and ALL national study groups. Such collaboration appears essential for proper interpretation of our results. Subsequent conferences (Milan 2012, Marseille 2013) reviewed modern trends in pharmacotherapy and immunotherapy. The most recent meeting focused on unrelated donor transplantations took place in Paris on 29th November 2014 and was very well attended (see program below). Additionally, ALWP recently contributed to organization of another conference held in Paris on 30th

January 2015: "Master Classes in Transplantation and Hematology (MATH): A focus on conditioning". Our activity is possible thanks to a collaborative work of all EBMT members who report their data, ALWP

data managers (headed by Emmanuelle Polge) and our statistician (Myriam Labopin). We thank you all for your continuous support and wish you brilliant ideas as well as successful, innovative studies.

Subcommittee	Leader	e.mail address
Acute lymphoblastic leukemia	Sebastian Giebel	sgiebel@io.gliwice.pl
Alternative donors	Fabio Ciceri	ciceri.fabio@hsr.it
Autologous SCT	Norbert Claude Gorin	norbert-claude.gorin@sat.aphp.fr
Cord blood transplantation	Frederic Baron	f.baron@ulg.ac.be
Immunotherapy	Christoph Schmid	christoph.schmid@klinikum-augsburg.de
Molecular markers	Jordi Esteve	jesteve@clinic.ub.es
Reduced intensity conditioning	Bipin Savani	bipin.savani@Vanderbilt.Edu

Chairman

Arnon Nagler
 Chaim Sheba Medical Center
 Tel-Hashomer, Israel
 Email: arnon.nagler@sheba.health.gov.il



Secretary

Sebastian Giebel
 Maria Skłodowska-Curie Memorial
 Cancer Centre & Institute of Oncology
 Gliwice, Poland
 Email: sgiebel@io.gliwice.pl



ALWP 2014 PUBLICATIONS

Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia? Ringdén O, Labopin M, Solders M, Beelen D, Arnold R, Ehninger G, Milpied N, Niederwieser D, Hamladji RM, Kyrz-Krzemien S, Ganser A, Socié G, Stelljes M, Volin L, Craddock C, Mohty M; Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. *Transplantation*. 2014; 98: 569-77.

Improving results of autologous stem cell transplantation for Philadelphia-positive acute lymphoblastic leukaemia in the era of tyrosine kinase inhibitors: a report from the Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Giebel S, Labopin M, Gorin NC, Caillot D, Leguay T, Schaap N, Michallet M, Dombret H, Mohty M. *Eur J Cancer*. 2014; 50: 411-7.

Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT. Kharfan-Dabaja MA, Labopin M, Bazarbachi A, Hamladji RM, Blaise D, Socié G, Lioure B, Bermudez A, Lopez-Corral L, Or R, Arcese W, Fegueux N, Nagler A, Mohty M. *Bone Marrow Transplant*. 2014; 49: 1170-5.

Prediction of non-relapse mortality in recipients of reduced intensity conditioning allogeneic stem cell transplantation with AML in first complete remission. Versluis J, Labopin M, Niederwieser D, Socié G, Schlenk RF, Milpied N, Nagler A, Blaise D, Rocha V, Cornelissen JJ, Mohty M. *Leukemia*. 2015; 29: 51-7.

Intravenous busulfan for autologous stem cell transplantation in adult patients with acute myeloid leukemia: a survey of 952 patients on behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Nagler A, Labopin M, Gorin NC, Ferrara F, Sanz MA, Wu D, Gomez AT, Lapusan S, Irrera G, Guimaraes JE, Sousa AB, Carella AM, Vey N, Arcese W, Shimoni A, Berger R, Rocha V, Mohty M. *Haematologica*. 2014; 99:1380-6.

Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: a survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Giebel S, Mischczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, Gorin NC, Labopin M, Nagler A, Schmid C, Mohty M. *Cancer*. 2014; 120: 2760-5.

Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome. Nagler A, Labopin M, Berger R, Bunjes D, Campos A, Socié G, Kröger N, Goker H, Yakoub-Agha I, Shimoni A, Mohty M, Rocha V. *Bone Marrow Transplant*. 2014; 49: 628-33.

Impact of minimal residual disease on outcomes after umbilical cord blood transplantation for adults with Philadelphia-positive acute lymphoblastic leukaemia: an analysis on behalf of Eurocord, Cord Blood Committee and the Acute Leukaemia working party of the European group for Blood and Marrow Transplantation. Tucunduva L, Ruggeri A, Sanz G, Furst S, Cornelissen J, Linkesch W, Mannone L, Ribera JM, Veelken H, Yakoub-Agha I, González Valentín ME, Schots R, Arcese W, Montesinos P, Labopin M, Gluckman E, Mohty M, Rocha V. *Br J Haematol*. 2014;166: 749-57.

A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S, Gorin NC, Doc Y, Wu D, Beelen D., Tischer J, Ehninger G, Arcese W, Nagler A, Mohty M. *Leukemia* in press 2014.

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socié G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M. *Bone Marrow Transplant.* 2014; 49: 389-96.

Impact of postremission consolidation chemotherapy on outcome after reduced-intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia in first complete remission: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Yeshurun M, Labopin M, Blaise D, Cornelissen JJ, Sengeloev H, Vindelov L, Kuball J, Chevallier P, Craddock C, Socié G, Bilger K, Schouten HC, Fegueux N, Goker H, Maertens J, Bunjes D, Arnold R, Nagler A, Mohty M. *Cancer.* 2014; 120: 855-63.

Chemotherapy dose adjustment for obese patients undergoing hematopoietic stem cell transplantation: A survey on behalf of the acute leukemia working party of the EBMT. Shem-Tov N, Schmid C, Ciceri F, Esteve J, Giebel S, Nagler A, Mohty M. *The Oncologist.* 2015; 20: 50-5.

Tyrosine kinase inhibitors improve outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome acute lymphoblastic leukemia in first complete remission: a study from the Acute Leukemia Working Party of EBMT. Brissot E, Labopin M, Beckers MM, Socié G, Rambladi A, Volin L, Finke J, Lenhoff S, Kroger N, Ossenkoppele GJ, Craddock CF, Yakoub-Agha I, Gurman G, Russell NH, Aljurf M, Potter MN, Nagler A, Ottmann O, Cornelissen JJ, Esteve J, Mohty M. *Haematologica.* 2015;100: 392-399.

Reduced intensity conditioning with Fludarabine and Busulfan versus Fludarabine and Melphalan for patients with acute myeloid leukemia given grafts from HLA-identical siblings: a report from the Acute Leukemia Working Party of the European group for Blood and Marrow Transplantation. Baron F, Labopin M, Peniket A, Jindra P, Afanasyev B, Sanz MA, Deconinck E, Nagler A, Mohty M. *Cancer*, in press 2014

Use of G-CSF to hasten neutrophil recovery after auto-SCT for AML is not associated with increased relapse incidence: a report from the Acute Leukemia Working Party of the EBMT. Czerw T, Labopin M, Gorin NC, Giebel S, Blaise D, Dumas PY, Foa R, Attal M, Schaap N, Michallet M, Bonmati C, Veelken H, Mohty M. *Bone Marrow Transplant.* 2014; 49: 950-4.

A prospective registration study to determine feasibility of hematopoietic SCT in adults with acute leukemia: planning, expectations and reality. Labopin M, Gorin NC, Polge E, Socié G, Gurman G, Gluckman E, Jindra P, Poiré X, Schäfer-Eckart K, Ruutu T, Milone G, Arcese W, Mohty M, Rocha V. *Bone Marrow Transplant.* 2014; 49:376-81.

ALWP ORAL PRESENTATIONS DURING ASH 2014

(SAN FRANCISCO, December 5-8th)

- Jordi Esteve, et al. Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Abstract #324.
- Jurjen Versluis, et al. The Hierarchy of Alternative Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Poor Risk AML in CR1: 10/10 Matched Unrelated Donors Still to be Preferred over Haplo-Identical Donors or Umbilical Cord Blood. Abstract #681.
- Arnon Nagler, et al. RIC Allo-SCT with Flu/Bu in Comparison to Flu/Mel for AML Results in Similar Overall Survival: A Report from the ALWP of the EBMT. Abstract #324.
- Tomasz Czerw, et al. Impact of CD3+ and CD34+ Doses in the Mobilized Peripheral Blood Stem Cell Grafts on the Outcome of Reduced-Intensity Conditioning Allogeneic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia – an Analysis from the Acute Leukemia Working Party of the EBMT. Abstract #681.
- Olaf Penack, et al. Influence of Preexisting Invasive Aspergillosis on Allo-HSCT Outcome: A Retrospective EBMT Analysis from the Infectious Diseases and Acute Leukemia Working Parties. Abstract #185.
- Raynier Devillier, et al. Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT. Abstract #729.
- Erick Xavier, et al. Double Cord Blood Transplantation: Incidence, Organ Involvement and Risk Factors of Acute Graft Versus Host Disease. A Retrospective Analysis on Behalf of Eurocord, ALWP and CQLWP-EBMT. Abstract #187.

UNRELATED DONOR HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE LEUKEMIA (PARIS, November 29th, 2014)

Session 1 : Donor availability

- Introduction: ALWP chair (Arnon Nagler, Israel) and local host - (Mohamad Mohty, France)
- Availability of unrelated donors: Example of the development of the Polish unrelated donors registry - (Jerzy Holowiecki, Poland)
- HLA and T cells in unrelated transplants: Basic concepts, functional matching - (Katharina Fleischhauer, Germany)
- HLA mis-matching in MUD as a way to reduce relapse? - (Bipin Savani, USA)

Session 2 : Impact of conditioning

- Comparison of sibling donors vs. 10/10 MUD in the standard myeloablative setting - (Ibrahim Yakoub-Agha, France)
- The role of ATG: Optimal dosage and timing? - (Frederic Baron, Belgium)
- Evolution of chemotherapy-based preparative regimens for acute leukemia - (Arnon Nagler, Israel)
- Evolution of radiation-based preparative regimens - (Sebastian Giebel, Poland)

Keynote lecture

Low dose IL-2 for GVHD prevention and therapy? - (David Klatzman, France)

Session 3. Indications for URD-HSCT

- AML - (Jan J. Cornelissen - The Netherlands)
- ALL - (Anthony Goldstone, UK)
- Alternative donors vs. URD-HSCT: haploidentical transplants, cord blood? - (Fabio Ciceri, Italy)
- Autologous HSCT vs. URD-HSCT? - (Norbert-Claude Gorin, France)

